BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer
November 14, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Nov. 14, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that its Board of Directors has appointed Stephen P....
BG Medicine Reports 2013 Third Quarter Financial Results
November 06, 2013 07:35 ET
|
BG Medicine, Inc.
Capital Health Accountable Care Organization LLC Adopts BGM Galectin-3® Test
Network of Laboratories in U.S. Offering BGM Galectin-3Test Expanded
Full-Year 2013 Product Revenue and Cash...
SilverStaff Clinical Laboratories to Offer BGM Galectin-3(R) Test
November 06, 2013 07:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test and SilverStaff Clinical Laboratories, Inc. today announced that SilverStaff...
BG Medicine to Announce Third Quarter 2013 Financial Results and Host Conference Call on Wednesday, November 6, 2013
October 30, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Oct. 30, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Wednesday, November 6 at 8:30 a.m. Eastern...
BG Medicine Announces Preliminary Decision by CMS on Reconsideration of Reimbursement for BGM Galectin-3 Test
September 30, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Sept. 30, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have made a preliminary decision to set the...
BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT Study Conducted at Massachusetts General Hospital Demonstrating Predictive Value of Adverse Outcomes in Heart Failure Patients
September 23, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of the results of a clinical research study conducted at the Massachusetts General...
BG Medicine, Inc. Announces Schedule of Events Related to Galectin-3 at the 17th Annual Scientific Meeting of the Heart Failure Society of America
September 19, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Sept. 19, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the...
BG Medicine, Inc. to Present at the Baird 2013 Health Care Conference
September 04, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the...
BG Medicine Reports 2013 Second Quarter Financial Results and Provides Second Half Outlook
August 08, 2013 07:45 ET
|
BG Medicine, Inc.
Focusing Investments on Increasing U.S. and EU Galectin-3 Adoption
2013 Financial and Operational Guidance Provided
WALTHAM, Mass., Aug. 8, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc....
BG Medicine to Announce Second Quarter 2013 Financial Results and Host Conference Call on Thursday, August 8, 2013
August 01, 2013 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, August 8 at 8:30 a.m. Eastern...